MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial.

Nat Commun · 2025 · PMC11704051 · PMID 39762248

Europe PMC DOI

hedged sentence

0.0550

closest p · 1.1× alpha

0.0550

boldest claim

The sentences

did not reach statistical significancep = 0.055so close (0.05 < p ≤ 0.1)

However, the strong trend toward reduction in SDMA levels did not reach statistical significance (p = 0.055), likely due to the limited sample size.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.